{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:34:32Z","timestamp":1740123272060,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100007514","name":"University of Pisa","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007514","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s10637-019-00804-5","type":"journal-article","created":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T12:38:00Z","timestamp":1559392680000},"page":"92-98","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacological effects of the simultaneous and sequential combinations of trifluridine\/tipiracil (TAS-102) and 5-fluorouracil in fluoropyrimidine-sensitive colon cancer cells"],"prefix":"10.1007","volume":"38","author":[{"given":"Paola","family":"Orlandi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Banchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Cucchiara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Di Desidero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Cremolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Moretto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Falcone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7120-9141","authenticated-orcid":false,"given":"Guido","family":"Bocci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,1]]},"reference":[{"issue":"7","key":"804_CR1","doi-asserted-by":"publisher","first-page":"659","DOI":"10.7150\/ijms.24453","volume":"15","author":"J Sanchez-Gundin","year":"2018","unstructured":"Sanchez-Gundin J, Fernandez-Carballido AM, Martinez-Valdivieso L, Barreda-Hernandez D, Torres-Suarez AI (2018) New trends in the therapeutic approach to metastatic colorectal cancer. Int J Med Sci 15(7):659\u2013665. https:\/\/doi.org\/10.7150\/ijms.24453","journal-title":"Int J Med Sci"},{"issue":"1","key":"804_CR2","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/biomedicines6010034","volume":"6","author":"Nelson Yee","year":"2018","unstructured":"Yee NS (2018) Update in systemic and targeted therapies in gastrointestinal oncology. Biomedicines 6(1). https:\/\/doi.org\/10.3390\/biomedicines6010034","journal-title":"Biomedicines"},{"issue":"2","key":"804_CR3","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.soc.2017.11.001","volume":"27","author":"C Wu","year":"2018","unstructured":"Wu C (2018) Systemic therapy for colon cancer. Surg Oncol Clin N Am 27(2):235\u2013242. https:\/\/doi.org\/10.1016\/j.soc.2017.11.001","journal-title":"Surg Oncol Clin N Am"},{"issue":"16","key":"804_CR4","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.2217\/fon-2018-0147","volume":"14","author":"M Peeters","year":"2018","unstructured":"Peeters M, Cervantes A, Moreno Vera S, Taieb J (2018) Trifluridine\/tipiracil: an emerging strategy for the management of gastrointestinal cancers. Future Oncol 14(16):1629\u20131645. https:\/\/doi.org\/10.2217\/fon-2018-0147","journal-title":"Future Oncol"},{"issue":"3","key":"804_CR5","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3892\/etm.2011.244","volume":"2","author":"N Suzuki","year":"2011","unstructured":"Suzuki N, Nakagawa F, Nukatsuka M, Fukushima M (2011) Trifluorothymidine exhibits potent antitumor activity via the induction of DNA double-strand breaks. Exp Ther Med 2(3):393\u2013397. https:\/\/doi.org\/10.3892\/etm.2011.244","journal-title":"Exp Ther Med"},{"issue":"4","key":"804_CR6","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1158\/1535-7163.mct-09-0932","volume":"9","author":"OH Temmink","year":"2010","unstructured":"Temmink OH, Bijnsdorp IV, Prins HJ, Losekoot N, Adema AD, Smid K, Honeywell RJ, Ylstra B, Eijk PP, Fukushima M, Peters GJ (2010) Trifluorothymidine resistance is associated with decreased thymidine kinase and equilibrative nucleoside transporter expression or increased secretory phospholipase A2. Mol Cancer Ther 9(4):1047\u20131057. https:\/\/doi.org\/10.1158\/1535-7163.mct-09-0932","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"804_CR7","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1158\/1078-0432.ccr-16-2157","volume":"23","author":"L Marcus","year":"2017","unstructured":"Marcus L, Lemery SJ, Khasar S, Wearne E, Helms WS, Yuan W, He K, Cao X, Yu J, Zhao H, Wang Y, Stephens O, Englund E, Agarwal R, Keegan P, Pazdur R (2017) FDA approval summary: TAS-102. Clin Cancer Res 23(12):2924\u20132927. https:\/\/doi.org\/10.1158\/1078-0432.ccr-16-2157","journal-title":"Clin Cancer Res"},{"issue":"5","key":"804_CR8","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrc1074","volume":"3","author":"DB Longley","year":"2003","unstructured":"Longley DB, Harkin DP, Johnston PG (2003) 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3(5):330\u2013338. https:\/\/doi.org\/10.1038\/nrc1074","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"804_CR9","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1158\/1535-7163.mct-14-0236","volume":"14","author":"K Matsuoka","year":"2015","unstructured":"Matsuoka K, Iimori M, Niimi S, Tsukihara H, Watanabe S, Kiyonari S, Kiniwa M, Ando K, Tokunaga E, Saeki H, Oki E, Maehara Y, Kitao H (2015) Trifluridine induces p53-dependent sustained G2 phase arrest with its massive misincorporation into dna and few dna strand breaks. Mol Cancer Ther 14(4):1004\u20131013. https:\/\/doi.org\/10.1158\/1535-7163.mct-14-0236","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"804_CR10","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.21873\/anticanres.12367","volume":"38","author":"T Baba","year":"2018","unstructured":"Baba T, Kokuryo T, Yamaguchi J, Yokoyama Y, Uehara K, Ebata T, Nagino M (2018) Pre-exposure to fluorouracil increased Trifluridine incorporation and enhanced its anti-tumor effect for colorectal cancer. Anticancer Res 38(3):1427\u20131434. https:\/\/doi.org\/10.21873\/anticanres.12367","journal-title":"Anticancer Res"},{"issue":"13","key":"804_CR11","first-page":"4026","volume":"50","author":"I Brunetti","year":"1990","unstructured":"Brunetti I, Falcone A, Calabresi P, Goulette FA, Darnowski JW (1990) 5-fluorouracil enhances azidothymidine cytotoxicity: in vitro, in vivo, and biochemical studies. Cancer Res 50(13):4026\u20134031","journal-title":"Cancer Res"},{"issue":"7","key":"804_CR12","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/0959-8049(96)00018-4","volume":"32","author":"M. Andreuccetti","year":"1996","unstructured":"Andreuccetti M, Allegrini G, Antonuzzo A, Malvaldi G, Conte PF, Danesi R, Del Tacca M, Falcone A (1996) Azidothymidine in combination with 5-fluorouracil in human colorectal cell lines: in vitro synergistic cytotoxicity and DNA-induced strand-breaks. Eur J Cancer 32A (7):1219\u20131226","journal-title":"European Journal of Cancer"},{"issue":"3","key":"804_CR13","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"TC Chou","year":"2006","unstructured":"Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58(3):621\u2013681. https:\/\/doi.org\/10.1124\/pr.58.3.10","journal-title":"Pharmacol Rev"},{"issue":"3","key":"804_CR14","doi-asserted-by":"publisher","first-page":"e531","DOI":"10.1016\/j.clcc.2018.04.002","volume":"17","author":"AK Patel","year":"2018","unstructured":"Patel AK, Duh MS, Barghout V, Yenikomshian MA, Xiao Y, Wynant W, Tabesh M, Fuchs CS (2018) Real-world treatment patterns among patients with colorectal cancer treated with Trifluridine\/Tipiracil and Regorafenib. Clin Colorectal Cancer 17(3):e531\u2013e539. https:\/\/doi.org\/10.1016\/j.clcc.2018.04.002","journal-title":"Clin Colorectal Cancer"},{"issue":"6","key":"804_CR15","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1080\/14656566.2018.1453497","volume":"19","author":"N Mulet","year":"2018","unstructured":"Mulet N, Matos I, Noguerido A, Martini G, Elez ME, Argiles G, Tabernero J (2018) Evaluating trifluridine + tipiracil hydrochloride in a fixed combination (TAS-102) for the treatment of colorectal cancer. Expert Opin Pharmacother 19(6):623\u2013629. https:\/\/doi.org\/10.1080\/14656566.2018.1453497","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"804_CR16","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00280-005-0033-4","volume":"57","author":"OH Temmink","year":"2006","unstructured":"Temmink OH, Hoogeland MF, Fukushima M, Peters GJ (2006) Low folate conditions may enhance the interaction of trifluorothymidine with antifolates in colon cancer cells. Cancer Chemother Pharmacol 57(2):171\u2013179. https:\/\/doi.org\/10.1007\/s00280-005-0033-4","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"804_CR17","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.3390\/ijms19102915","volume":"19","author":"Kazuaki Matsuoka","year":"2018","unstructured":"Matsuoka K, Nakagawa F, Tanaka N, Okabe H, Matsuo K, Takechi T (2018) Effective sequential combined chemotherapy with Trifluridine\/Tipiracil and regorafenib in human colorectal cancer cells. Int J Mol Sci 19(10). https:\/\/doi.org\/10.3390\/ijms19102915","journal-title":"International Journal of Molecular Sciences"},{"issue":"12","key":"804_CR18","first-page":"2577","volume":"7","author":"K Matsuoka","year":"2017","unstructured":"Matsuoka K, Takechi T (2017) Combined efficacy and mechanism of trifluridine and SN-38 in a 5-FU-resistant human colorectal cancer cell lines. Am J Cancer Res 7(12):2577\u20132586","journal-title":"Am J Cancer Res"},{"issue":"10","key":"804_CR19","first-page":"2032","volume":"7","author":"N Suzuki","year":"2017","unstructured":"Suzuki N, Tsukihara H, Nakagawa F, Kobunai T, Takechi T (2017) Synergistic anticancer activity of a novel oral chemotherapeutic agent containing trifluridine and tipiracil in combination with anti-PD-1 blockade in microsatellite stable-type murine colorectal cancer cells. Am J Cancer Res 7(10):2032\u20132040","journal-title":"Am J Cancer Res"},{"issue":"6","key":"804_CR20","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.21873\/anticanres.11634","volume":"37","author":"J Gong","year":"2017","unstructured":"Gong J, Chen Y, Yang L, Pillai R, Shirasawa S, Fakih M (2017) MEK162 enhances antitumor activity of 5-fluorouracil and Trifluridine in KRAS-mutated human colorectal cancer cell lines. Anticancer Res 37(6):2831\u20132838. https:\/\/doi.org\/10.21873\/anticanres.11634","journal-title":"Anticancer Res"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00804-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-019-00804-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00804-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:41:56Z","timestamp":1678560116000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-019-00804-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["804"],"URL":"https:\/\/doi.org\/10.1007\/s10637-019-00804-5","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"type":"print","value":"0167-6997"},{"type":"electronic","value":"1573-0646"}],"subject":[],"published":{"date-parts":[[2019,6,1]]},"assertion":[{"value":"24 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study, formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}